Pharmacokinetics of bisphenol A in humans following dermal administration

• Published in: Environment international Vol. 144; p. 106031
• Main Authors: Sasso, Alan F., Pirow, Ralph, Andra, Syam S., Church, Rebecca, Nachman, Rebecca M., Linke, Susanne, Kapraun, Dustin F., Schurman, Shepherd H., Arora, Manish, Thayer, Kristina A., Bucher, John R., Birnbaum, Linda S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.11.2020; Elsevier
• Subjects: Absorption; Administration, Cutaneous; Administration, Oral; Benzhydryl Compounds; Bioavailability; bisphenol A; blood serum; dermal exposure; Distribution; Endocrine disruptor; environment; Excretion; Female; Half-Life; Humans; Male; Metabolism; oral administration; pharmacokinetics; Phenols; urinalysis; urine; Excretion; Endocrine disruptor; Absorption; Bioavailability; Metabolism; Distribution
• ISSN: 0160-4120; 1873-6750; 1873-6750
• DOI: 10.1016/j.envint.2020.106031

•We dermally administered deuterated BPA to 10 subjects at 100 µg/kg over 12 h.•We conducted blood and urine analysis from the beginning of dosing through 3–6 days.•We present time-course serum and urine concentrations of total and free d6-BPA.•Free d6-BPA was a greater percentage of total serum BPA when compared to oral data.•Dermal exposure resulted in a longer half-life when compared to oral data.•Approximately 2.2% of the dermal dose became systemically available. Human exposures to bisphenol A (BPA) are widespread. The current study addresses uncertainties regarding human pharmacokinetics of BPA following dermal exposure. To examine the absorption, distribution, metabolism and excretion of BPA in humans following dermal administration. We dermally administered deuterated BPA (d6-BPA) to 10 subjects (6 men and 4 women) at a dose of 100 µg/kg over a 12-hour period and conducted blood and urine analysis from the beginning of dosing through a three- or six-day period. We present time-course serum and urine concentrations of total and unconjugated (“free”) d6-BPA and used this information to calculate terminal half-life and area under the curve. Detectable serum levels of total d6-BPA were observed at 1.4 h after the start of dosing, and a maximum serum concentration (Cmax) of 3.26 nM was observed. Free d6-BPA was detectable in serum 2.8 h after start of dermal administration, with Cmax of 0.272 nM. Beginning at approximately seven hours and continuing to 12 h (which corresponds to cessation of exposure), the concentration of free and total serum d6-BPA plateaued. The terminal half-lives of total d6-BPA and free d6-BPA in the body were 21.4 ± 9.81 h and 17.6 ± 7.69 h, respectively. Elimination from the body was rate-limited by kinetics in the dermal compartment. Free d6-BPA was a greater percentage of the area under the curve of total serum BPA (8.81%) compared to the 0.56% observed in our previously published oral study. Recovery of total d6-BPA in urine was <2% of the applied dose after six days. Analysis of the area under the curve for dermal and oral administration revealed that 2.2% of the dermal dose became systemically available. These data are in line with prior studies indicating how pharmacokinetics of BPA differ following oral and dermal exposures. Dermal exposure resulted in a longer apparent half-life and higher free:total d6-BPA ratio compared to oral.